Results 231 to 240 of about 778,808 (360)

Controlled trial of cervical cancer screening frequency among human‐papillomavirus‐vaccinated women

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Since the introduction of the human papillomavirus (HPV) vaccine in 2006, vaccine‐type infections have declined markedly. As nonvaccine HPV types generally carry lower oncogenic potential, this shift warrants reevaluation of cervical screening regimens.
Mònica Ortega Llobet   +10 more
wiley   +1 more source

The Short-Term Impacts of Japan's 2024 Physician Working-Hour Limits on Labor Conditions, Self-Directed Professional Development, and Happiness Among Obstetrician-Gynecologists. [PDF]

open access: yesJ Obstet Gynaecol Res
Maeda Y   +27 more
europepmc   +1 more source

Fertility preservation in women with sarcoma: A real‐world experience

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Sarcomas frequently affect adolescent girls and young women, but limited data exist on ovarian function following sarcoma treatment. This observational cohort study evaluated the feasibility, timing, and clinical relevance of fertility preservation in young women treated for high‐grade sarcomas or desmoid tumors.
Guillaume Beinse   +11 more
wiley   +1 more source

Doppel as an early‐stage biomarker promoting EMT and dissemination in ovarian cancers

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Existing biomarkers for ovarian cancer (OC) lack the sensitivity and specificity needed to consistently distinguish the malignancy from non‐ovarian influences and other cancers. Here, the authors explored the ability of the prion‐like protein Doppel, normally found in the male testes, to detect OC.
Zulfikar Azam   +18 more
wiley   +1 more source

Detecting TP53 mutations in paired liquid and tissue biopsies from patients with high‐grade serous ovarian carcinoma

open access: yesInternational Journal of Cancer, EarlyView.
What's New? High‐grade serous ovarian carcinoma is often diagnosed at advanced stages due to non‐specific symptoms and the lack of reliable screening methods. This proof‐of‐concept study introduces a novel TP53 mutation panel using unique molecular identifier‐based next‐generation sequencing for sensitive detection of high‐grade serous ovarian ...
Amanda Olsson Widjaja   +11 more
wiley   +1 more source

Correction: Effect of orally administered L. crispatus M247 in favoring HR-HPV clearance and CST shift: results from a randomized, multi-center, placebo-controlled trial. [PDF]

open access: yesSci Rep
Di Pierro F   +17 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy